Cinctive Capital Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.54M Buy
+64,153
New +$5.7M 0.23% 130
2025
Q4
– Sell
-77,956
Closed -$6.06M – 428
2025
Q3
$6.06M Sell
77,956
-78,272
-50% -$6.12M 0.29% 112
2025
Q2
$12.2M Buy
156,228
+59,278
+61% +$4.42M 0.65% 40
2025
Q1
$7.03M Sell
96,950
-51,973
-35% -$3.72M 0.54% 53
2024
Q4
$11M Buy
148,923
+92,963
+166% +$6.51M 0.56% 45
2024
Q3
$3.69M Buy
+55,960
New +$4.07M 0.2% 167
2024
Q2
– Sell
-33,333
Closed -$3.19M – 430
2024
Q1
$3.19M Buy
+33,333
New +$2.8M 0.15% 174
2023
Q1
– Sell
-41,599
Closed -$3.1M – 449
2022
Q4
$3.1M Buy
+41,599
New +$3.21M 0.15% 209
2022
Q3
– Sell
-25,560
Closed -$2.43M – 506
2022
Q2
$2.43M Sell
25,560
-12,064
-32% -$1.25M 0.1% 291
2022
Q1
$4.43M Sell
37,624
-34,309
-48% -$3.85M 0.16% 208
2021
Q4
$9.32M Buy
71,933
+62,110
+632% +$7.24M 0.41% 75
2021
Q3
$1.11M Sell
9,823
-57,006
-85% -$6.51M 0.05% 382
2021
Q2
$6.92M Buy
66,829
+64,212
+2,454% +$6.05M 0.32% 92
2021
Q1
$219K Buy
+2,617
New +$221K 0.01% 390

Other funds holding EW

Cinctive Capital Management's EW Position: Q3 2026 in Review

Cinctive Capital Management opened a new position in Edwards Lifesciences (EW) in Q3 2026: 64,153 shares worth $5.54M. The stake represents 0.23% of the portfolio and ranks #130 among its holdings. This is a return to the name: Cinctive Capital Management previously reported a position in EW as recently as Q3 2025.

Cinctive Capital Management first reported a position in EW in Q1 2021 and has held it in 14 quarters since. The position peaked at $12.2M in Q2 2025. 1,345 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Cinctive Capital Management held 64,153 shares of Edwards Lifesciences worth $5.54M as of Q3 2026.
  • Edwards Lifesciences was a new Cinctive Capital Management position in Q3 2026.
  • Edwards Lifesciences made up 0.23% of Cinctive Capital Management's portfolio in Q3 2026, its #130 holding.
  • Cinctive Capital Management first reported a position in Edwards Lifesciences in Q1 2021 and has held it in 14 quarters since.
  • Cinctive Capital Management's Edwards Lifesciences position peaked at $12.2M in Q2 2025.
  • 1,345 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Cinctive Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.